Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Not applicable

Sleep Well At Night

NCT07068971 · tracked via the Priya Life Science Ireland tracker
Phase
Not applicable
Started
2024-08-19
Last updated
2025-07-16

Condition(s) studied

Sleep Disturbance in Advanced Cancer

Investigational drug(s) / intervention(s)

Online cognitive behavioural therapy for insomnia, bright light therapy, activity

Online cognitive behavioural therapy for insomnia, bright light therapy, activity: Multimodal intervention

Study summary

Research has shown that the incidence of sleep disturbances in people with cancer is much higher than in the general population. Sleep problems can lead to worse symptoms, quality of life, and potentially impact outcomes. The most common treatment of sleep disturbances is medication which often comes with unwanted side-effects and risk. This study aims to test whether a non-drug intervention can be given to people with cancer to help with sleep disturbances.

The study will take place over 8-weeks. The first and final week of the study involves assessments (further described below) while the intervention will take place over weeks 2-7. The intervention involves an online cognitive behavioural therapy course, daily bright light therapy and engaging with an activity plan.

The initial review aims to identify any reversible causes of the sleep disturbance, including reviewing uncontrolled symptoms and medications.

Cognitive behavioural therapy for insomnia (CBT-I) has been shown to be effective at improving the time it takes for people to fall asleep and reducing the amount of time you wake up in the night.

Light therapy mimics our natural exposure to sunlight. Light exposure may help to improve sleep during the night, mood, and activity or attention levels during the day.

Physical activity levels will also be reviewed. Interests and barriers to activity will be discussed and goals will be set for activity. This will be reviewed weekly.

Questionnaires will be completed in the first and final week of the study to assess sleep, symptoms and quality of life. Wrist actigraphy, thigh accelerometry and a sleep diary will also be used on the first and final week of the study to assess sleep, activity and subjective sleep patterns.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. 18 years old and over 2. Diagnosis of advanced cancer (locally advanced, metastatic) 3. Subjective sleep disturbance 4. Total score of 5 or more on PSQI 5. Eastern Cooperative Oncology Group (ECOG) performance status 1-3 6. Attending outpatients (oncology and/or palliative care) 7. Estimated prognosis of \> 3 months Exclusion Criteria: 1. Inpatient 2. ECOG performance status 4 3. Cognitive impairment limiting the ability to complete assessment tools and sleep diary 4. Engaged in shift work 5. A recent exacerbation of symptoms (e.g. pain/nausea/dyspnoea) which may impact sleep 6. History of uncontrolled mania or bipolar disorder 7. Recent history or current thoughts of self-harm or suicide 8. Recent change in antidepressant medication

Primary outcome measure(s)

  • Retention rate — through study completion - 8 weeks
    considering the number of patients who entered the study and completed the study.
  • Recruitment — one year
    considering the number of patients approached to take part in the study who then entered the study
  • Completion of the intervention — 8 weeks
    Considering engagement with various interventions. The case report form will capture engagement with online cognitive behavioural therapy for insomnia where progress can be viewed online and the sleep diary will be reviewed. The participant will report on use of the bright light therapy box and activity levels throughout the study.
  • Acceptability — 8 weeks
    A patient acceptability questionnaire of various aspects of the study, including interventions and study protocol, will be completed at the end of the study.

Trial sites (1)

FacilityCityRegionStatus
Our Lady's Hospice & Care Services Dublin Ireland
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07068971 on ClinicalTrials.gov ↗ ← All trials in Ireland